ARTICLE | Clinical News

Erbitux cetuximab: Phase II data

November 15, 2010 8:00 AM UTC

An Austrian Phase II trial in 30 patients showed that Erbitux plus Gemzar gemcitabine and oxaliplatin (GEMOX) chemotherapy produced 3 complete responses and 16 partial responses. Median PFS and OS were 8.8 and 15.2 months, respectively. In 9 patients who underwent potentially curative secondary resection after major response to therapy, median PFS was 21.2 months vs. 6.8 months for patients who did not have surgery (p=0.0001). Data were published in The Lancet. ...